Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR4640 in primary gout with hyperuricemia
CTR20211140Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruzinurad in gout, hyperuricemia, sponsored by Hengrui Therapeutics. Started May 2021; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20211140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211140.